BioPharmSignal logoBioPharmSignal

Biotech News

Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors

Annexon, Inc. (ANNX)Annexon, Inc.Company update

Over Four Decades of Clinical, Scientific and Corporate Leadership Advancing Innovation in Retinal Disease BRISBANE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple

Related news

ANNXAnnexon, Inc.2026-08-12 10:00 EST

Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study

ANNXAnnexon, Inc.2026-08-06 12:00 EST

Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week

VTGNVistagen Therapeutics, Inc.2026-07-31 12:30 EST

Vistagen Appoints Douglas J. Williamson to its Board of Directors

ANLAdlai Nortye Ltd.2026-09-30 11:00 EST

Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations

ALKSAlkermes plc2026-09-16 11:00 EST

Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors

ECORelectroCore2026-09-09 12:00 EST

electroCore, Inc. Appoints Joshua Lev and Mike Fox as Co-Chief Executive Officers

AXSMAxsome2026-09-17 11:00 EST

Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026

SNYSanofi2026-10-01 05:00 EST

Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies

NBIXNeurocrine Biosciences2026-09-30 12:30 EST

Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference

GANXGain Therapeutics2026-09-29 21:50 EST

Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders

View all latest news

Annexon, Inc.

Classical Complement Inhibition Annexon develops therapies that inhibit the classical complement pathway, which can drive harmful inflammation and tissue damage in neurologic, ophthalmic, and autoimmune diseases. Tanruprubart Tanruprubart is an antibody therapy for Guillain-Barré syndrome. Its European marketing application is under...

Recent company news

ANNXAnnexon, Inc.2026-09-24 12:00 EST

Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting

ANNXAnnexon, Inc.2026-09-16 20:05 EST

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

ANNXAnnexon, Inc.2026-09-02 12:00 EST

Annexon to Participate in Upcoming September Investor Conferences

ANNXAnnexon, Inc.2026-08-17 20:05 EST

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

ANNXAnnexon, Inc.2026-08-12 10:05 EST

Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

Stock data

Close
4.03 USD
Market cap
861.81M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States